Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will earn $0.05 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.28) per share.
A number of other equities analysts have also recently commented on the stock. HC Wainwright reissued a "buy" rating on shares of Esperion Therapeutics in a research note on Friday, January 10th. StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.30.
View Our Latest Research Report on ESPR
ESPR stock opened at $2.15 on Wednesday. The firm has a market cap of $423.64 million, a PE ratio of -3.36 and a beta of 1.03. The firm has a fifty day moving average price of $2.46 and a 200 day moving average price of $2.18. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $51.63 million during the quarter, compared to the consensus estimate of $55.44 million. During the same period in the previous year, the firm posted ($0.37) earnings per share.
A number of hedge funds and other institutional investors have recently bought and sold shares of ESPR. Boomfish Wealth Group LLC boosted its holdings in shares of Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,102 shares during the period. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $28,000. Traphagen Investment Advisors LLC bought a new position in shares of Esperion Therapeutics during the 3rd quarter worth $27,000. Mackenzie Financial Corp increased its stake in shares of Esperion Therapeutics by 104.8% during the second quarter. Mackenzie Financial Corp now owns 35,254 shares of the biopharmaceutical company's stock valued at $78,000 after buying an additional 18,036 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Esperion Therapeutics by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company's stock valued at $3,414,000 after acquiring an additional 19,588 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.